^
    11d
    APG2575CC201: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL (clinicaltrials.gov)
    P2, N=75, Recruiting, Ascentage Pharma Group Inc. | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Sep 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    lisaftoclax (APG-2575)
    28d
    Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    lisaftoclax (APG-2575)
    1m
    A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    clonoSEQ
    |
    cytarabine • pelcitoclax (APG-1252) • lisaftoclax (APG-2575) • fludarabine IV
    2ms
    Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study (clinicaltrials.gov)
    P1/2, N=122, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • lisaftoclax (APG-2575) • Polivy (polatuzumab vedotin-piiq)
    2ms
    A Prospective, Single-Arm, Multicenter Study on the Efficacy and Safety of Lisaftoclax Combined with Rituximab and Lenalidomide Regimen in the Treatment of Previously Untreated Elderly Patients with Mantle Cell Lymphoma (ChiCTR2500115112)
    P=N/A, N=40, Not yet recruiting, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University; Jiangsu Province Hospital, The First Affiliated Hospital of Na
    New trial
    |
    Rituxan (rituximab) • lenalidomide • lisaftoclax (APG-2575)
    2ms
    Clinical Study on Efficacy and Safety of G-CSF Combined with Azacitidine and Venetoclax in the Treatment of Adult Acute Myeloid Leukemia (ChiCTR2500112100)
    P=N/A, N=34, Not yet recruiting, The Second Affiliated Hospital of Guangxi Medical University; The Second Affiliated Hospital of Guangxi Medical University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • lisaftoclax (APG-2575)
    4ms
    Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease (clinicaltrials.gov)
    P2, N=25, Recruiting, Ruijin Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • lisaftoclax (APG-2575)
    4ms
    Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL (clinicaltrials.gov)
    P2, N=29, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • lisaftoclax (APG-2575)
    6ms
    APG2575AC101: Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (clinicaltrials.gov)
    P1/2, N=458, Recruiting, Ascentage Pharma Group Inc. | N=284 --> 458 | Trial completion date: Aug 2026 --> Sep 2029 | Trial primary completion date: Aug 2025 --> Sep 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    azacitidine • Nailike (olverembatinib) • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    7ms
    Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=62, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P1/2 trial • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    8ms
    MAPLE-1: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (clinicaltrials.gov)
    P1, N=46, Completed, Ascentage Pharma Group Inc. | Trial completion date: Feb 2024 --> Aug 2025
    Trial completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lisaftoclax (APG-2575)
    12ms
    Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL (clinicaltrials.gov)
    P1, N=144, Recruiting, Ascentage Pharma Group Inc. | N=35 --> 144 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Oct 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    lisaftoclax (APG-2575)